A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 199(2019) vom: 10. Feb., Seite 29-36
1. Verfasser: Seluk, Lior (VerfasserIn)
Weitere Verfasser: Taliansky, Alisa, Yonath, Hagith, Gilburd, Boris, Amital, Howard, Shoenfeld, Yehuda, Kivity, Shaye
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Autoantibodies Autoimmune diseases Autoimmunity Cancer Paraneoplastic neurological syndromes Small cell lung cancer CNTNAP2 protein, human ELAV Proteins Membrane Proteins mehr... Nerve Tissue Proteins Receptors, N-Methyl-D-Aspartate
LEADER 01000naa a22002652 4500
001 NLM291739083
003 DE-627
005 20231225071532.0
007 cr uuu---uuuuu
008 231225s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2018.12.007  |2 doi 
028 5 2 |a pubmed24n0972.xml 
035 |a (DE-627)NLM291739083 
035 |a (NLM)30543927 
035 |a (PII)S1521-6616(18)30716-2 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Seluk, Lior  |e verfasserin  |4 aut 
245 1 2 |a A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.12.2019 
500 |a Date Revised 02.12.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2018 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: Paraneoplastic neurological syndromes (PNS) are a group of syndromes that affect the central and peripheral neuromuscular system in association with cancer. Specific antibodies may assist in the diagnosis of PNS. The antibodies tested can be classified into those directed against intracellular neuronal proteins ("well characterized" PNS: Hu, Yo, RI, CV2, amphiphysin, Ma1, Ma2) and those directed against neural surface antigens (autoimmune encephalitis syndromes: NMDA, AMPA, LGI1, CASPR2, GABAR). We aimed to characterize patients with unexplained neuropsychiatric symptoms, in whom positive PNS antibodies were detected in the Sheba medical center, a large referral hospital 
520 |a METHODS: Clinical and demographic data of patients with positive PNS antibodies were collected during the years 2002-2016. Antibodies were tested by either Line immunoassay or by cell-based indirect immunofluorscent assay 
520 |a RESULTS: During the follow up of 14 years, 4010 PNS tests were performed in patients with unexplained neuropsychiatric symptoms. Seventy-two were found to be positive; among them we had full clinical data access to 44. The most frequent antibodies were anti-Hu (31.8%), anti-Yo (18.2%), anti-CV2 (13.6%), and anti-NMDA (9.1%), and the most common cancers were small-cell lung (SCLC) and ovarian cancers. In the well characterized paraneoplastic group, cancer was diagnosed in 55.9% of the patients, and in the autoimmune encephalitis group, 40.0% were diagnosed with cancer. A positive correlation between antibody titer and the presence of cancer was found. Ninety percent of the tests in patients who were found positive were ordered by a neurologist or neuro-oncologist 
520 |a CONCLUSIONS: The titers of PNS auto-antibodies can predict cancer in patients whom anti-PNS antibodies are tested. In addition, consultation with a specialist should be considered before this test is ordered 
650 4 |a Journal Article 
650 4 |a Autoantibodies 
650 4 |a Autoimmune diseases 
650 4 |a Autoimmunity 
650 4 |a Cancer 
650 4 |a Paraneoplastic neurological syndromes 
650 4 |a Small cell lung cancer 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a CNTNAP2 protein, human  |2 NLM 
650 7 |a ELAV Proteins  |2 NLM 
650 7 |a Membrane Proteins  |2 NLM 
650 7 |a Nerve Tissue Proteins  |2 NLM 
650 7 |a Receptors, N-Methyl-D-Aspartate  |2 NLM 
700 1 |a Taliansky, Alisa  |e verfasserin  |4 aut 
700 1 |a Yonath, Hagith  |e verfasserin  |4 aut 
700 1 |a Gilburd, Boris  |e verfasserin  |4 aut 
700 1 |a Amital, Howard  |e verfasserin  |4 aut 
700 1 |a Shoenfeld, Yehuda  |e verfasserin  |4 aut 
700 1 |a Kivity, Shaye  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 199(2019) vom: 10. Feb., Seite 29-36  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:199  |g year:2019  |g day:10  |g month:02  |g pages:29-36 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2018.12.007  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 199  |j 2019  |b 10  |c 02  |h 29-36